Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH
New results from the Phase 1b/2a ACTH-dependent Cushing's syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower d
Login to comment